| Code | CSB-RA008545MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to rozanolixizumab, targeting the neonatal Fc receptor (FCGRT). FCGRT plays a critical role in regulating IgG antibody homeostasis by binding immunoglobulin G in a pH-dependent manner, protecting IgG from lysosomal degradation and extending its serum half-life. This receptor is expressed on various cell types including endothelial cells, epithelial cells, and antigen-presenting cells. FCGRT is particularly relevant in autoimmune diseases where pathogenic IgG autoantibodies drive tissue damage, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris.
Rozanolixizumab is a high-affinity humanized IgG4 monoclonal antibody that blocks FCGRT, thereby accelerating the catabolism of circulating IgG antibodies and reducing pathogenic autoantibody levels. This biosimilar provides researchers with a valuable tool for investigating FCGRT-mediated IgG recycling mechanisms, studying autoantibody-driven pathologies, and exploring therapeutic strategies for autoimmune disorders. It enables investigation of antibody pharmacokinetics and immune regulation in experimental models.
There are currently no reviews for this product.